Miacalcic (Calcitonin Salmon, Synthetic)

Calcitonin salmon is a synthetic analogue of the natural hormone calcitonin. It binds to calcitonin receptors on osteoclasts, the cells responsible for breaking down bone, thereby inhibiting their activity. This reduces bone resorption, lowers serum calcium concentrations, and can provide analgesic effects in bone pain.

The specific dose and administration schedule of Miacalcic are determined by the prescribing clinician based on the patient’s condition, age, renal function, and other individual factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic outcomes while minimising potential adverse effects.

Safety data for calcitonin salmon in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Miacalcic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Miacalcic (calcitonin salmon) differs from bisphosphonates and denosumab in its mechanism; it directly inhibits osteoclast activity via calcitonin receptors, whereas the others affect bone resorption through different pathways. Calcitonin often provides rapid pain relief and is useful when other agents are contraindicated, but its long‑term efficacy may be lower than that of bisphosphonates.

Miacalcic should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary temperature excursions occur, consult the product’s stability guidelines before use.

Miacalcic is supplied as an injectable solution and can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical indication and physician preference. Administration is performed by a qualified healthcare professional using aseptic technique, and the injection site should be monitored for local reactions.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, marked hypocalcemia leading to neuromuscular symptoms, and rare cases of acute renal impairment. Patients should be observed for signs of allergic response and have serum calcium monitored regularly during therapy.

Miacalcic is contraindicated in individuals with known hypersensitivity to calcitonin salmon or any component of the formulation. It should also be avoided in patients receiving duplicate calcitonin therapy or those for whom the risk of severe hypocalcemia outweighs potential benefits, as determined by their healthcare provider.